Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
about
Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention StrategiesPrevention of Hepatitis B reactivation in the setting of immunosuppressionKASL clinical practice guidelines: management of chronic hepatitis BOccult hepatitis B virus infectionAcute leukemia in children: A review of the current Indian dataHepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-ScreenedManagement of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.Cost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors.Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure.A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic ChemotherapySystematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.Horizontal transmission of de novo hepatitis B between spouses: A case report.Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy.Prevention of HBV reactivation in patients treated with biologic agents.Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy.Immunosuppression in Patients with Chronic Hepatitis B.Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.
P2860
Q26746486-8C80C5C7-7308-4E7F-A54B-273EA815AC96Q26747023-149902E6-9A8A-4938-A0BA-FBE3E625DE99Q26752475-966F9100-E860-4D1A-AF39-F4219FB2C1BEQ27004224-A47ECF25-21DA-48E8-902F-E037B99D2DE4Q28066885-4696575C-C521-4BF4-80AE-F08B9361B8B1Q28076703-DE480CF9-2C2D-4A7F-B6A4-F3DCE00173D8Q33762835-B0D36B29-334B-4FDA-AA66-ECB2723572EDQ33872813-C9F90FC6-7144-45DE-A0F1-BB6E48514DD6Q35375654-2ABF2843-8F58-470A-A5DB-EDAC3DA48AF5Q35567748-46D1EBBC-4AF0-486A-B43B-923AD11E018CQ35677319-85EA8872-11E5-4A7F-BB87-E001C3C64198Q36001152-4812AFA2-3000-4510-A78B-2801BC04DB22Q40191470-A022227B-CCED-4B2D-96FF-E34B023936AAQ40642803-A2467F82-0FEC-48EA-B23D-B126C650BE70Q40830395-8AE651F7-A779-45C3-82DC-EB9498E82644Q40870495-5EEC9030-3C03-4C10-B10F-28375D4ECF68Q42224704-DBAB0C66-29B5-4B64-8828-389B0E9BA4D1Q42764680-9D934F65-DB3E-426F-8647-259FDE0ADA96Q45326378-9D2BCF92-5B0E-4F75-89FF-52008E176351
P2860
Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Entecavir versus lamivudine fo ...... s with haematological disease.
@en
Entecavir versus lamivudine fo ...... s with haematological disease.
@nl
type
label
Entecavir versus lamivudine fo ...... s with haematological disease.
@en
Entecavir versus lamivudine fo ...... s with haematological disease.
@nl
prefLabel
Entecavir versus lamivudine fo ...... s with haematological disease.
@en
Entecavir versus lamivudine fo ...... s with haematological disease.
@nl
P2093
P2860
P356
P1433
P1476
Entecavir versus lamivudine fo ...... s with haematological disease.
@en
P2093
Brett E Jones
Fei W Chen
Luke Coyle
Venessa Pattullo
P2860
P304
P356
10.1111/LIV.12154
P577
2013-03-24T00:00:00Z